Some people think that the amount of data in IVD ranks first in the medical industry. It is a very good segment, the market is very large, and the future space is very large. For entrepreneurs, this one will be a very good choice. Others believe that IVD is already a Red Sea market and it is very difficult to do. So what is the domestic IVD market?

IVD in vitro diagnostic industry profile

IVD (In Vitro Diagnosis) refers to the detection of a sample taken out of the human body, relative to in vivo diagnosis. The reagents and instruments are required during the detection process, and these reagents and instruments constitute an in vitro diagnostic system. The enterprises engaged in the research, development, production and marketing of these reagents and instruments form the in vitro diagnostic industry.

Usually it is one or several reagents, coupled with a device, used to detect several to dozens of items. Some companies specialize in the production of reagents, but most companies' marketing models are instruments + reagents. Some manufacturers use "send equipment + sell reagents", because the reagents are consumables, the hospital will continue to purchase; of course, there are manufacturers, equipment and reagents sold at the same time.

Overview of IVD industry development

There are many different market segments in the entire IVD field, and in 2014 it was about 43 billion. According to the diagnostic method, clinical biochemistry and immunodiagnosis add up to nearly 50% share, which is comparable. Compared with the near-mature biochemistry and immunization, the growth point of the global market is mainly concentrated on molecular diagnosis, POCT, etc., and has great potential.

Third-party laboratory (ICL) development prospects

The third-party laboratory is a professional central laboratory for hospitals to outsource inspection services to achieve medical savings. In the United States and Europe, third-party laboratories have become the mainstream and mature business model in the diagnostic market, accounting for about 40% of the in vitro diagnostic market.

But will ICL become mainstream in China?

In China, because the medical reform and regulation of drug prices have reduced the profit margin of hospitals, most hospitals have chosen to use the laboratory to generate income, so there is no incentive to outsource diagnostic projects. In addition, independent laboratories of large-scale roads often undertake projects with large sample sizes but low gross profit margins. Due to the serious competition of homogenization and low outsourcing prices, the industry's profitability is generally weak.

Canned Cereal

canned rea bean , canned mung bean, canned grass jelly, canned chestnut, canned safflower bean, canned oats, canned purple rice, canned purple potato, canned taro,canned babao bean

cereal can, canned goods, canned corn,tin can

KARAK , https://www.jskarak.com